ALCL
MCID: ANP001
MIFTS: 57

Anaplastic Large Cell Lymphoma (ALCL) malady

Categories: Rare diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

Aliases & Descriptions for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 38 12 50 56 29 52 14
Alcl 50 56
Cd30 Positive Anaplastic Large Cell Lymphoma 56
Ki-1 Positive Anaplastic Large Cell Lymphoma 56
Ki-1+ Anaplastic Large Cell Lymphoma 69
Primary Systemic Alcl 56
Sacl 56

Characteristics:

Orphanet epidemiological data:

56
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050744
Orphanet 56 ORPHA98841
MESH via Orphanet 43 D017728
ICD10 via Orphanet 34 C84.6 C84.7

Summaries for Anaplastic Large Cell Lymphoma

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as alcl, is related to hemophagocytic lymphohistiocytosis and neurofibromatosis. An important gene associated with Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Adcetris and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone, and related phenotypes are hematopoietic system and immune system

Wikipedia : 71 Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
id Related Disease Score Top Affiliating Genes
1 hemophagocytic lymphohistiocytosis 30.3 ALK NPM1 PAX5 TNFRSF8
2 neurofibromatosis 29.8 NPM1 PAX5 PTPRC
3 alk-positive anaplastic large cell lymphoma 12.5
4 alk-negative anaplastic large cell lymphoma 12.5
5 primary cutaneous anaplastic large cell lymphoma 12.3
6 lymphoma 11.2
7 anaplastic small cell lymphoma 11.1
8 lymphomatoid papulosis 10.4
9 hodgkin lymphoma 10.4
10 malignant glioma 10.2 GZMB TIA1
11 penile disease 10.2 ALK PTPRC TNFRSF8
12 alström syndrome 10.2 GZMB TIA1
13 cecum adenoma 10.2 ALK NPM1 RNF213
14 omodysplasia 2 10.2 MUC1 PTPRC TNFRSF8
15 leukemia 10.2
16 skeletal muscle cancer 10.2 GZMB TIA1
17 b-cell lymphomas 10.2
18 tibial adamantinoma 10.2 GZMB TIA1
19 hinman syndrome 10.2 PAX5 PTPRC
20 slc16a1-related hyperinsulinism 10.1 IL9 JAK3
21 basal ganglia disease 10.1 GZMB PAX5 TNFRSF8
22 pre-malignant neoplasm 10.1 GZMB TIA1 TNFRSF8
23 peripheral t-cell lymphoma 10.1
24 ectodermal dysplasia 10.1 ALK PAX5 TNFRSF8
25 superior limbic keratoconjunctivitis 10.1 GZMB TIA1
26 macrogyria, pseudobulbar palsy and mental retardation 10.1 ALK GZMB NPM1 TIA1
27 uterine ligament endometrioid adenocarcinoma 10.1 GZMB PAX5 TIA1
28 estrogen-receptor negative breast cancer 10.1 ALK NPM1 PTPRC TIA1
29 glossopharyngeal nerve disease 10.1 CSF1R PTPRC TNFRSF8
30 subacute delirium 10.1 ALK PAX5 PTPRC TNFRSF8
31 developmental coordination disorder 10.1 CSF1R PTPRC
32 sarcoma 10.1
33 cutis laxa 10.0 CLU CSF1R
34 collagen type iii glomerulopathy 10.0 GZMB TIA1
35 diffuse large b-cell lymphoma 10.0
36 dermatitis 10.0
37 mycosis fungoides 10.0
38 histiocytosis 10.0
39 inflammatory myofibroblastic tumor 10.0
40 cerebritis 10.0
41 post-transplant lymphoproliferative disease 10.0 ALK CXCR3 GZMB TIA1
42 marantic endocarditis 10.0 ALK NPM1 PAX5 TIA1 TNFRSF8
43 myeloid leukemia 9.9
44 adult t-cell leukemia 9.9
45 soft tissue sarcoma 9.9
46 panniculitis 9.9
47 t-cell leukemia 9.9
48 complication after organ transplantation 9.9 ALK JAK3 MCL1 MUC1 NPM1 STAT3
49 single ventricular heart 9.9 IL9 JAK3 PTPRC
50 congenital sucrase-isomaltase deficiency with starch and lactose intolerance 9.9 ALK GZMB MUC1 NPM1 PTPRC TIA1

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CSF1R CXCR3 IL9 JAK3 MCL1 NPM1
2 immune system MP:0005387 9.97 TNFRSF8 TNFSF8 CLU CSF1R CXCR3 IL9
3 endocrine/exocrine gland MP:0005379 9.92 JAK3 MCL1 PTPRC RNF213 STAT3 TNFRSF8
4 neoplasm MP:0002006 9.43 ALK CXCR3 NPM1 PAX5 PTPRC STAT3
5 normal MP:0002873 9.23 CSF1R CXCR3 IL9 MCL1 PAX5 PTPRC

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics Approved August 2011

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23214-92-8 31703
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
6
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
11
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
12
Mechlorethamine Approved Phase 4,Phase 1,Phase 2 51-75-2 4033
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
14
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
15
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
16
Vindesine Approved Phase 4 59917-39-4, 53643-48-4 40839
17
Epirubicin Approved Phase 4 56420-45-2 41867
18
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
21
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2 31703
22
Pirarubicin Investigational Phase 4 72496-41-4
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
26 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
39 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1
41 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
42 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
45 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Hormones Phase 4,Phase 3,Phase 2,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
49 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 381)
id Name Status NCT ID Phase
1 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Recruiting NCT01746992 Phase 4
3 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4
4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4
5 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4
6 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3
7 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
9 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
11 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed NCT00059839 Phase 3
12 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
13 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
14 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3
15 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3
16 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3
17 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3
18 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
19 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
20 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
21 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
23 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
24 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
25 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
26 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
27 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
29 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
30 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
31 Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Recruiting NCT02201992 Phase 3
32 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Recruiting NCT02737501 Phase 3
33 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
34 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3
35 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3
36 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3
37 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
38 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
39 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00073957 Phase 2
40 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Unknown status NCT01336933 Phase 2
41 A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Unknown status NCT01449461 Phase 1, Phase 2
42 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
43 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
44 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
45 Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse Unknown status NCT00069966 Phase 2
46 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2
47 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2
48 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2
49 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
50 Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Completed NCT00079755 Phase 2

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

id Genetic test Affiliating Genes
1 Anaplastic Large Cell Lymphoma 29

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

39
T Cells, Breast, Bone, Skin, Bone Marrow, B Cells, Lymph Node

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 963)
id Title Authors Year
1
Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation. ( 28497585 )
2017
2
The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma. ( 28331184 )
2017
3
Primary Bone Anaplastic Large Cell Lymphoma Masquerading as Ewing Sarcoma: Diagnosis by Anchored Multiplex PCR. ( 28452858 )
2017
4
Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex. ( 27840423 )
2017
5
NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma. ( 27694894 )
2017
6
Indolent ALK-Negative Anaplastic Large Cell Lymphoma, DUSP22 Rearranged, with an Unusual Immunophenotype in an HIV Patient. ( 28042680 )
2017
7
Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. ( 27766622 )
2017
8
Discussion: Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma. ( 27219222 )
2016
9
PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma. ( 28013563 )
2016
10
Clinical and histopathologic overlap between subcutaneous panniculitis-like T-cell lymphoma with systemic features and small cell CD8+ ALK+ systemic anaplastic large cell lymphoma with cutaneous involvement. ( 27060878 )
2016
11
Paraneoplastic Dermatosis in a Patient with Anaplastic Large-Cell Lymphoma: Case Report and Literature Review. ( 27504444 )
2016
12
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. ( 27795556 )
2016
13
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. ( 27460479 )
2016
14
Novel Technique for Sampling of Breast Implant-associated Seroma in Anaplastic Large Cell Lymphoma. ( 27200250 )
2016
15
NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma. ( 27773932 )
2016
16
A Snowy White Stomach, Caused by Primary Gastric Anaplastic Large-Cell Lymphoma. ( 27546582 )
2016
17
Anaplastic large cell lymphoma masquerading as osteomyelitis of the shoulder: an uncommon presentation. ( 28003232 )
2016
18
ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis. ( 27563714 )
2016
19
Fulminant anaplastic large cell lymphoma (ALCL) concomitant with primary cytomegalovirus (CMV) infection, and human herpes virus 8 (HHV-8) infection together with Epstein-Barr-virus (EBV) reactivation in a patient with asymptomatic HIV-infection. ( 27551290 )
2016
20
Primary cutaneous anaplastic large-cell lymphoma: a case report. ( 26970422 )
2016
21
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large cell lymphoma. ( 27037558 )
2016
22
Rapidly Progressive Acute Pustular Secondary Cutaneous Anaplastic Large Cell Lymphoma. ( 27602978 )
2016
23
Primary Cutaneous Anaplastic Large-Cell Lymphoma With 6p25.3 Rearrangement in a Cardiac Transplant Recipient: A Case Report and Review of the Literature. ( 26863058 )
2016
24
Change in the diagnosis from classical Hodgkin's lymphoma to anaplastic large cell lymphoma by (18)F flourodeoxyglucose positron emission tomography/computed tomography: Importance of recognising disease pattern on imaging and immunohistochemistry. ( 26917898 )
2016
25
Primary cutaneous anaplastic large cell lymphoma in a child simulating primary cutaneous Hodgkin's disease. ( 26728828 )
2016
26
Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature. ( 27612448 )
2016
27
Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. ( 27859003 )
2016
28
Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. ( 27473193 )
2016
29
Loss of CD30 Expression in Anaplastic Large Cell Lymphoma Following Brentuximab Therapy. ( 27391642 )
2016
30
Anaplastic Large Cell Lymphoma and Vanishing Bile Duct Syndrome. ( 26958553 )
2016
31
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. ( 27103829 )
2016
32
Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 27095311 )
2016
33
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. ( 27793034 )
2016
34
Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma. ( 26984254 )
2016
35
Relapses of primary cutaneous anaplastic large-cell lymphoma in a female immunocompetent patient with persistent chlamydophila pneumoniae and human herpesvirus 8 infection. ( 27382410 )
2016
36
Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 26979456 )
2016
37
Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate. ( 27874877 )
2016
38
Sinusoidal CD30+ diffuse large B-cell lymphoma can masquerade as anaplastic large cell lymphoma in pediatric posttransplant lymphoproliferative disorders. ( 28035754 )
2016
39
Fine-needle aspiration cytology yield as a basis for morphological, molecular, and cytogenetic diagnosis in alk-positive anaplastic large cell lymphoma with atypical clinical presentation. ( 27468968 )
2016
40
Discussion: Anaplastic Large Cell Lymphoma in the Plastic Surgery Practice: Has It Influenced Practice Patterns? ( 27782988 )
2016
41
The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma. ( 26709646 )
2016
42
Breast Implant and Anaplastic Large Cell Lymphoma Meta-Analysis. ( 27537783 )
2016
43
A positive feedback loop involving the Wnt/I^-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. ( 27821172 )
2016
44
Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. ( 26753883 )
2016
45
Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma. ( 27498729 )
2016
46
Anaplastic large cell lymphoma in paediatric and young adult patients. ( 26913827 )
2016
47
Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. ( 26734914 )
2016
48
Primary cutaneous anaplastic large cell lymphoma masquerading as large pyogenic granuloma. ( 27990392 )
2016
49
Synchronous Occurrence of Primary Cutaneous Anaplastic Large Cell Lymphoma and Squamous Cell Carcinoma. ( 27489433 )
2016
50
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. ( 27538486 )
2016

Variations for Anaplastic Large Cell Lymphoma

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CLU CSF1R IL9 JAK3 MCL1 MUC1
2
Show member pathways
13.68 ALK CSF1R CXCR3 IL9 JAK3 MUC1
3
Show member pathways
13.46 ALK CSF1R CXCR3 IL9 JAK3 STAT3
4
Show member pathways
13.15 ALK CSF1R CXCR3 IL9 JAK3 STAT3
5
Show member pathways
13.03 CSF1R IL9 JAK3 MCL1 MUC1 STAT3
6 12.26 GZMB JAK3 PAX5 PTPRC STAT3
7
Show member pathways
12.03 IL9 JAK3 MCL1 STAT3
8
Show member pathways
11.72 GZMB JAK3 STAT3
9 11.61 JAK3 MCL1 MUC1 STAT3
10 11.4 CSF1R JAK3 PTPRC STAT3
11
Show member pathways
11.3 IL9 JAK3 STAT3
12
Show member pathways
11.26 CSF1R JAK3 STAT3
13 11.22 JAK3 PTPRC STAT3
14 11.16 CXCR3 GZMB IL9 PTPRC
15 10.89 GZMB MCL1
16 10.65 PAX5 PTPRC STAT3 TNFRSF8

GO Terms for Anaplastic Large Cell Lymphoma

Cellular components related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 ALK CSF1R CXCR3 MUC1 PTPRC TNFRSF8

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.86 ALK CSF1R CXCR3 NPM1 STAT3 TFG
2 apoptotic process GO:0006915 9.43 CLU CXCR3 GZMB MCL1 TIA1 TNFSF8
3 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.16 JAK3 STAT3
4 inflammatory response GO:0006954 9.1 CSF1R CXCR3 IL9 JAK3 STAT3 TNFRSF8

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 CSF1R JAK3 STAT3

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....